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Background
Patients with familial adenomatous polyposis (FAP) are
perceived to be at increased risk for developing thyroid
cancer. However, screening guidelines for thyroid cancer
in FAP patients are not well established. To report the
prevalence of thyroid cancer and benign thyroid disease
in FAP patients in a single-center hereditary colorectal
cancer registry.
Methods
A retrospective chart review of all FAP patients enrolled
in the MKSCC Hereditary Colorectal Cancer Family
Registry was performed.
Results
Sixty six patients with FAP were identified in the regis-
try. This included 30 men and 36 women, with current
mean age of 40.6 years. Four patients (6.1%) had a his-
tory of thyroid cancer (TC), and underwent thyroidect-
omy. All TC patients were women, with mean age at
cancer diagnosis of 36 years. Three of the 4 known TC
diagnoses were papillary thyroid cancer. One patient
initially presented with tender thyroid nodule. Another
patient with attenuated FAP and a documented APC
R332X mutation had a nodule detected on ultrasound.
APC mutation testing in the other 3 TC patients is not
known. An additional 6 FAP patients (9.1%) were diag-
nosed with benign thyroid disease, including one with
Hashimoto’s thyroiditis, 2 with thyroid nodules, 1 with
thyroid cysts, and 2 with multinodular goiter.
Conclusion
The prevalence of thyroid cancer in our FAP population
(6.1%) is increased relative to the general population,
and is within the range of that reported by others (1-
12%). We are also intrigued by the frequency of benign
thyroid disease in this population. We are embarking on
a systematic thyroid screening program in our FAP
patients.
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